Aviance Capital Partners LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,204 shares of the medical research company’s stock after purchasing an additional 919 shares during the period. Amgen makes up approximately 2.2% of Aviance Capital Partners LLC’s investment portfolio, making the stock its 6th largest holding. Aviance Capital Partners LLC’s holdings in Amgen were worth $6,752,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Camelot Portfolios LLC acquired a new stake in shares of Amgen during the first quarter worth $1,429,000. PGGM Investments grew its stake in shares of Amgen by 2.3% during the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after purchasing an additional 15,059 shares during the period. Shelton Capital Management grew its stake in shares of Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares during the period. Cadence Bank NA grew its stake in shares of Amgen by 6.2% during the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after purchasing an additional 197 shares during the period. Finally, Telos Capital Management Inc. grew its stake in shares of Amgen by 1.6% during the first quarter. Telos Capital Management Inc. now owns 14,348 shares of the medical research company’s stock worth $2,354,000 after purchasing an additional 227 shares during the period. 78.14% of the stock is owned by institutional investors and hedge funds.

Several research analysts have weighed in on AMGN shares. Oppenheimer Holdings, Inc. set a $189.00 target price on Amgen and gave the stock a “buy” rating in a report on Tuesday, June 13th. BMO Capital Markets reiterated a “buy” rating and set a $198.00 target price (down from $200.00) on shares of Amgen in a report on Monday, May 22nd. ValuEngine upgraded Amgen from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Mizuho reiterated a “buy” rating and set a $195.00 target price on shares of Amgen in a report on Sunday, July 9th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $195.00 target price on shares of Amgen in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. Amgen has a consensus rating of “Buy” and a consensus price target of $186.04.

TRADEMARK VIOLATION NOTICE: This report was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/14/aviance-capital-partners-llc-buys-919-shares-of-amgen-inc-amgn.html.

Shares of Amgen Inc. (AMGN) traded up 0.21% during trading on Thursday, reaching $190.09. The company’s stock had a trading volume of 1,037,868 shares. The stock’s 50 day moving average price is $174.23 and its 200-day moving average price is $168.94. The firm has a market cap of $138.70 billion, a PE ratio of 17.31 and a beta of 1.35. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the firm earned $2.84 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts predict that Amgen Inc. will post $12.57 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a yield of 2.42%. Amgen’s payout ratio is 41.93%.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.